Nasdaq ardx.

Aug 31, 2023 · Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation. Analyst Price Forecast Suggests 77.74% Upside. As of August ... WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...5 equities research analysts have issued 12-month price targets for Ardelyx's shares. Their ARDX share price targets range from $7.00 to $11.00. On average, ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

Dec 1, 2023 · Ardelyx Inc (NASDAQ:ARDX)’s Major holders Ardelyx Inc insiders own 1.74% of total outstanding shares while institutional holders control 56.10%, with the float percentage being 57.09%. State Street Corporation is the largest shareholder of the company, while 176 institutions own stock in it. Oct 11, 2023 · Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...

Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ETCitigroup Inc. decreased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the ...Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ETPrivate Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The ...

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

S hares of Ardelyx ( NASDAQ: ARDX) were down 17% in afternoon trading Wednesday ahead of an expected FDA decision on its kidney disease treatment candidate Xphozah and amid a market-moving update ...25 thg 9, 2023 ... Ardelyx's (NASDAQ:ARDX) Kidney Disease Therapy Bags Approval in Japan ... Ardelyx's lead candidate, tenapanor, has bagged approval in Japan for ...Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock. Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press ...XPeng Inc. American depositary shares, each representing two Class A ordinary shares (XPEV) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ...U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The ...

25 thg 8, 2023 ... Cantor Fitzgerald, by way of analyst Louise Chen, upgraded Ardelyx to “overweight” in light of a very strong potential win. The analysts expect ...Ardelyx Inc (NASDAQ:ARDX) 4.34 Delayed Data As of Nov 17 +0.305 / +7.57% Today’s Change 1.56 Today ||| 52-Week Range 5.13 +52.11% Year-to-Date Quote Profile News …Ardelyx (NASDAQ:ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Ardelyx (NASDAQ:ARDX) is another hot penny stock to consider. The biotech stock, which has a market cap of $550 million and is trading at $2.94, could see higher highs.

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended …Nov 24, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ... Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...5 equities research analysts have issued 12-month price targets for Ardelyx's shares. Their ARDX share price targets range from $7.00 to $11.00. On average, ...Ardelyx, Inc. Reports Employment Inducement Grants. WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on …Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ET. +0.19 / +4.36%. Today’s Change. 1.67. Find the latest SEC Filings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, …

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ...Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.May 17, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... Oct 18, 2023 · The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ... Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. On this news, the Company’s stock price fell $0.70, or 13.4%, to close at $4.51 per share on May 26, 2021, on unusually heavy trading volume.Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.The restructuring drive implemented on August 02 is intended “to reduce operating costs and better align the Company’s workforce with the needs of its business,” Ardelyx (NASDAQ:ARDX) said ...

Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […] The bid-ask spread can indicate a stock's liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher ...In the latest trading session, Ardelyx (ARDX) closed at $3.02, marking a -1.63% move from the previous day. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added ...Instagram:https://instagram. all online banking appbest leverage forex brokersenova international inclord abbett bond debenture Shares of the small-cap biotech Ardelyx ( ARDX 1.62%) fell by a whopping 73.2% in pre-market action Tuesday morning. The drugmaker's stock is tanking today in response to a July 13 letter from the ... c8 70th anniversarysilver projection Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ... ndaq stock price Back to ARDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Plug Power, Inc. Common Stock. $9.46 -1.29 -12.00%. Ardelyx, Inc. Common Stock (ARDX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and ...